Royal Bank Of Canada Initiates Coverage on IQVIA (NYSE:IQV)

Royal Bank Of Canada started coverage on shares of IQVIA (NYSE:IQV) in a research report issued to clients and investors on Tuesday, MarketBeat.com reports. The brokerage set an “outperform” rating and a $221.00 price target on the medical research company’s stock. Royal Bank Of Canada’s price target would suggest a potential upside of 24.07% from the stock’s current price.

Several other brokerages have also issued reports on IQV. JPMorgan Chase & Co. cut their target price on shares of IQVIA from $255.00 to $225.00 and set an “overweight” rating for the company in a research report on Friday, February 6th. Morgan Stanley set a $240.00 price objective on IQVIA in a research note on Wednesday, February 11th. Evercore reissued an “outperform” rating and issued a $225.00 target price on shares of IQVIA in a research note on Thursday, February 5th. Jefferies Financial Group reduced their price objective on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, February 6th. Finally, UBS Group cut their price objective on IQVIA from $280.00 to $240.00 and set a “buy” rating on the stock in a research report on Friday, February 6th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $231.13.

IQVIA Trading Up 2.4%

IQV opened at $178.13 on Tuesday. The firm has a market capitalization of $30.23 billion, a PE ratio of 22.66, a P/E/G ratio of 1.68 and a beta of 1.39. The company has a debt-to-equity ratio of 2.09, a current ratio of 0.75 and a quick ratio of 0.75. IQVIA has a fifty-two week low of $134.65 and a fifty-two week high of $247.04. The company’s 50-day moving average is $209.22 and its 200 day moving average is $207.69.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 earnings per share for the quarter, beating the consensus estimate of $3.40 by $0.02. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The business had revenue of $4.36 billion for the quarter, compared to analysts’ expectations of $4.24 billion. During the same period last year, the business earned $3.12 EPS. The business’s revenue was up 10.3% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, research analysts predict that IQVIA will post 10.84 earnings per share for the current fiscal year.

Institutional Investors Weigh In On IQVIA

A number of institutional investors have recently bought and sold shares of IQV. Boston Partners purchased a new position in IQVIA during the 3rd quarter valued at approximately $676,698,000. Artisan Partners Limited Partnership bought a new stake in shares of IQVIA in the 2nd quarter valued at approximately $515,772,000. Norges Bank purchased a new position in shares of IQVIA in the 4th quarter worth approximately $497,445,000. Victory Capital Management Inc. increased its position in shares of IQVIA by 2,628.1% during the 4th quarter. Victory Capital Management Inc. now owns 1,675,479 shares of the medical research company’s stock valued at $377,670,000 after purchasing an additional 1,614,063 shares during the last quarter. Finally, Orbis Allan Gray Ltd raised its holdings in IQVIA by 96.5% during the 4th quarter. Orbis Allan Gray Ltd now owns 1,901,091 shares of the medical research company’s stock valued at $428,525,000 after buying an additional 933,554 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.